Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT‐751: A report from the Children's Oncology Group (ANBL0621)

ABT‐751, an orally bioavailable sulfonamide binds the colchicine site of beta‐tubulin and inhibits microtubule polymerizaton. Prior phase I studies established the recommended dose in children with solid tumors as 200 mg/m2 PO daily × 7 days every 21 days and subjects with neuroblastoma experienced prolonged stable disease. We conducted a phase 2 study (NCT00436852) in children and adolescents with progressive neuroblastoma to determine if ABT‐751 prolonged the time to progression (TTP) compared to a hypothesized standard based on a historical control population.

[1]  Helen X. Chen,et al.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.

[2]  H. Caron,et al.  Neuroblastoma: biology, prognosis, and treatment. , 2010, Hematology/oncology clinics of North America.

[3]  S. Steinberg,et al.  Clinical outcome in children with recurrent neuroblastoma treated with ABT‐751 and effect of ABT‐751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro , 2010, Pediatric blood & cancer.

[4]  J. Maris,et al.  A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors , 2008, Clinical Cancer Research.

[5]  P. Houghton,et al.  Evaluation of ABT-751 against childhood cancer models in vivo , 2007, Investigational New Drugs.

[6]  Steve Y. Cho,et al.  A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors , 2006, Clinical Cancer Research.

[7]  C. M. Galmarini.  ABT-751 (Abbott). , 2005, Current opinion in investigational drugs.

[8]  W. Abdullah.  Pediatr Blood Cancer , 2004 .

[9]  Michael Seid,et al.  The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. , 2003, Ambulatory pediatrics : the official journal of the Ambulatory Pediatric Association.

[10]  Robert F. Woolson,et al.  Rank Tests and a One-Sample Logrank Test for Comparing Observed Survival Data to a Standard Population , 1981 .

[11]  J. Maris,et al.  Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors , 2009, Cancer Chemotherapy and Pharmacology.

[12]  B. Asselain,et al.  A new 123I-MIBG whole body scan scoring method--application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. , 1995, European journal of cancer.